Assessment of the Evolution of Cancer Treatment Therapies
Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2011-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/3/3/3279/ |
| _version_ | 1797764371652280320 |
|---|---|
| author | Mónica Valladares Alejandro Tres Julio Lambea Berta Sáez-Gutierrez Manuel Arruebo Nuria Vilaboa África González-Fernández |
| author_facet | Mónica Valladares Alejandro Tres Julio Lambea Berta Sáez-Gutierrez Manuel Arruebo Nuria Vilaboa África González-Fernández |
| author_sort | Mónica Valladares |
| collection | DOAJ |
| description | Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present. |
| first_indexed | 2024-03-12T19:55:44Z |
| format | Article |
| id | doaj.art-32fbf54d880041d6a9181a6ee7afb238 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:55:44Z |
| publishDate | 2011-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-32fbf54d880041d6a9181a6ee7afb2382023-08-02T02:48:45ZengMDPI AGCancers2072-66942011-08-01333279333010.3390/cancers3033279Assessment of the Evolution of Cancer Treatment TherapiesMónica ValladaresAlejandro TresJulio LambeaBerta Sáez-GutierrezManuel ArrueboNuria VilaboaÁfrica González-FernándezCancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.http://www.mdpi.com/2072-6694/3/3/3279/cancerimmunotherapynanotechnologygene therapynanomedicine |
| spellingShingle | Mónica Valladares Alejandro Tres Julio Lambea Berta Sáez-Gutierrez Manuel Arruebo Nuria Vilaboa África González-Fernández Assessment of the Evolution of Cancer Treatment Therapies Cancers cancer immunotherapy nanotechnology gene therapy nanomedicine |
| title | Assessment of the Evolution of Cancer Treatment Therapies |
| title_full | Assessment of the Evolution of Cancer Treatment Therapies |
| title_fullStr | Assessment of the Evolution of Cancer Treatment Therapies |
| title_full_unstemmed | Assessment of the Evolution of Cancer Treatment Therapies |
| title_short | Assessment of the Evolution of Cancer Treatment Therapies |
| title_sort | assessment of the evolution of cancer treatment therapies |
| topic | cancer immunotherapy nanotechnology gene therapy nanomedicine |
| url | http://www.mdpi.com/2072-6694/3/3/3279/ |
| work_keys_str_mv | AT monicavalladares assessmentoftheevolutionofcancertreatmenttherapies AT alejandrotres assessmentoftheevolutionofcancertreatmenttherapies AT juliolambea assessmentoftheevolutionofcancertreatmenttherapies AT bertasaezgutierrez assessmentoftheevolutionofcancertreatmenttherapies AT manuelarruebo assessmentoftheevolutionofcancertreatmenttherapies AT nuriavilaboa assessmentoftheevolutionofcancertreatmenttherapies AT africagonzalezfernandez assessmentoftheevolutionofcancertreatmenttherapies |